Navigation Links
Mallinckrodt Completes Acquisition Of Questcor Pharmaceuticals
Date:8/14/2014

nts. Mallinckrodt has approximately 5,500 employees worldwide and a commercial presence in roughly 65 countries. The company's fiscal 2013 revenue totaled $2.2 billion. To learn more about Mallinckrodt, visit www.mallinckrodt.com.

Forward-Looking Statements
Statements in this document that are not strictly historical, including statements regarding the Questcor acquisition, future financial and operating results, benefits and synergies of the transaction, future opportunities for the combined businesses and any other statements regarding events or developments that we believe or anticipate will or may occur in the future, may be "forward-looking" statements within the meaning of the Private Securities Litigation Reform Act of 1995, and involve a number of risks and uncertainties. There are a number of important factors that could cause actual events to differ materially from those suggested or indicated by such forward-looking statements and you should not place undue reliance on any such forward-looking statements. These factors include risks and uncertainties related to, among other things: general economic conditions and conditions affecting the industries in which Mallinckrodt and Questcor operate; the commercial success of Mallinckrodt's and Questcor's products, including H.P. Acthar® Gel ("Acthar"); Mallinckrodt's and Questcor's ability to protect intellectual property rights; Mallinckrodt's ability to successfully integrate Questcor's operations and employees with Mallinckrodt's existing business; the ability to realize anticipated growth, synergies and cost savings; Questcor's performance and maintenance of important business relationships; the lack of patent protection for Acthar, and the possible United States Food and Drug Administration ("FDA") approval and market introduction of additional competitive products; Q
'/>"/>

SOURCE Mallinckrodt plc
Copyright©2014 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. FDA Grants Priority Review To New Drug Application For MNK-795 Submitted By Depomed Licensee Mallinckrodt
2. Mallinckrodt Pharmaceuticals And Questcor Pharmaceuticals Provide Update On Transaction
3. HeartWare Completes Enrollment In 450-Patient Pivotal Destination Therapy Clinical Trial
4. Novelos Therapeutics Successfully Completes First Cohort In Phase 1b Solid Tumor Trial With I-131-CLR1404 (HOT) Cancer-Targeted Molecular Radiotherapeutic
5. NuMe Health Completes $1.5 Million Series A Financing To Advance Its First Cobiotic™ Aimed At Helping Prediabetics Maintain Healthy Blood Glucose Levels
6. CryoLife Completes Acquisition of Hemosphere
7. Bausch + Lomb Completes the Acquisition of ISTA Pharmaceuticals
8. Savara Pharmaceuticals Completes Phase I Clinical Study of AeroVanc in Cystic Fibrosis Patients
9. Jazz Pharmaceuticals Completes EUSA Pharma Acquisition
10. Amgen Completes Acquisition of Mustafa Nevzat Pharmaceuticals
11. Ablative Solutions Completes $5.3M Series A Financing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/16/2014)... QPID Health , a leader in clinical intelligence software, today ... and their first West Coast location in San ... in Boston , and will house product development, ... Southern California office will be located at 1000 ... demands of customers nationwide.  Both new locations will be operational ...
(Date:9/16/2014)... Resources Group finds that the rheumatoid arthritis (RA) disease-modifying antirheumatic drug ... billion in 2023 in the United States , ... Italy , Spain , the ... TNF-alpha inhibitors will remain the leading drug class in both sales ... constrained and patient shares will decline due to the uptake of ...
(Date:9/16/2014)... 16, 2014  Formex, LLC ("Formex"), a ... Mr. Greg Weilersbacher joined Formex as Director of ... Greg Weilersbacher has over ... expertise in Quality Assurance, Facility Validation, GMP ... brings to Formex a diverse wealth of ...
Breaking Medicine Technology:QPID Health Announces Major Office Expansion in Boston and Opens Facility in San Diego 2The Rheumatoid Arthritis Drug Market Will Grow to $18.2 Billion in 2023, Driven by the Uptake of Oral Jak Inhibitors and Non TNF-alpha Biologics 2The Rheumatoid Arthritis Drug Market Will Grow to $18.2 Billion in 2023, Driven by the Uptake of Oral Jak Inhibitors and Non TNF-alpha Biologics 3Greg Weilersbacher Joins Formex, LLC As Director of Quality Assurance and Quality Control 2
... US Phase II Clinical Trials for Organ Transplantation, ... announces positive Phase I clinical results for,its transplantation ... clinical trials for organ transplantation. , Today LifeCycle ... I clinical trial program of LCP-Tacro, a,proprietary, once-daily ...
... Hemispherx Biopharma, Inc.,(AMEX: HEB), a biopharmaceutical company ... new drug entities for pandemic,disease threats, announced ... therapeutic product candidate Alferon-LDO in,combating highly pathogenic ... Alferon-LDO is a low-dose experimental oral formulation,of ...
Cached Medicine Technology:LifeCycle Pharma Announces Positive Phase I Clinical Results for,its Transplantation Product Candidate, LCP-Tacro 2LifeCycle Pharma Announces Positive Phase I Clinical Results for,its Transplantation Product Candidate, LCP-Tacro 3Hemispherx Presents Potential Avian Influenza Treatment,Breakthrough at Paris Conference 2Hemispherx Presents Potential Avian Influenza Treatment,Breakthrough at Paris Conference 3Hemispherx Presents Potential Avian Influenza Treatment,Breakthrough at Paris Conference 4
(Date:9/16/2014)... abnormalities in the adrenergic and noradrenergic systems, both ... play a role in the development of post-traumatic ... no genetic evidence of this connection. A collaborative ... Mailman School of Public Health and the University ... gene and childhood adversity. For individuals with two ...
(Date:9/16/2014)... (PRWEB) September 16, 2014 Beginning October 1st ... a new service offering for its clients who book a ... the volume of business they buy. Most recurring visit ... during the work week, but others include clients whose unique ... pet sitter on a daily basis. The newly ...
(Date:9/16/2014)... 16, 2014 The Pain Center ... by Ranking Arizona magazine, has selected Analance ™, ... enterprise. , With TPC seeing hundreds of thousands ... repository that was managed through “home grown” systems trying ... and clinical leadership teams. “Our current tools were ...
(Date:9/16/2014)... 2014 Founded by former Miami Beach ... a political organization fighting to legalize medical marijuana in ... The After Party recently commissioned a shot-for-shot parody video ... from the movie “Grease.” ( http://youtu.be/zdcvhUgeDRg ) , Called ... the musical parody faithfully recreates the carnival scene made ...
(Date:9/16/2014)... 16, 2014 Synergy Research Group has ... gives the best detail and analysis of the state ... a variety of sources, including Ministry of Health in ... will give readers actionable intelligence on clinical trials in ... relied on by the local and international life science ...
Breaking Medicine News(10 mins):Health News:Evidence of genetic link to PTSD in soldiers exposed to childhood trauma 2Health News:Evidence of genetic link to PTSD in soldiers exposed to childhood trauma 3Health News:Dallas-based Park Cities Pet Sitter Introduces New 15-Minute Visit for Clients on Recurring Visit Schedules. 2Health News:Dallas-based Park Cities Pet Sitter Introduces New 15-Minute Visit for Clients on Recurring Visit Schedules. 3Health News:The Pain Center of Arizona (TPC) Implements Analance™ BI for Actionable Intelligence 2Health News:The Pain Center of Arizona (TPC) Implements Analance™ BI for Actionable Intelligence 3Health News:Miami Beach Politician Drives 1,400 Miles to Texas to Shoot “Grease” Parody Video Supporting the Legalization of Medical Marijuana in Florida 2Health News:Synergy Research Group Debuts Ukraine Orange Paper 2
... , THURSDAY, Jan. 6 (HealthDay News) -- The ... death in newborn intensive care units (NICUs) would be eligible ... infants and young children, according to a new study. ... of the more than 200,000 people in the United States ...
... By Steven Reinberg HealthDay Reporter , WEDNESDAY, Jan. ... February 2007 must be reviewed by the U.S. Food and ... the agency announced Wednesday. This effort, one aspect of ... meant to keep more addictive products from the hands of ...
... non-profit organization focused on supporting innovative early career ... its fall Fellowship Award Committee review. The ... postdoctoral scientists conducting basic and translational cancer research ... the country. The Fellowship encourages the nation,s most ...
... Jan. 5 (HealthDay News) -- Women with multiple sclerosis are ... gene thought to be connected to the condition, a new ... more insight into the development of MS, which is becoming ... Although no one knows what causes MS, scientists suspect that ...
... lateral sclerosis (ALS), and frontotemporal lobar degeneration (FTLD) are ... that include an RNA-binding protein called TDP-43. This protein ... by these clumps. In a study published ... team led by Virginia M.-Y. Lee, PhD, director of ...
... China are reporting development of a less expensive, more eco-friendly ... it may be a more healthful form of water. Their ... Chemistry Research . Changgong Meng and Feng Huang ... a mixture of H2O and tiny amounts of D2O ...
Cached Medicine News:Health News:Infant Organ Donors Could Help Meet Transplant Needs: Study 2Health News:FDA Launches Review of Tobacco Products 2Health News:Damon Runyon Cancer Research Foundation awards prestigious fellowships to 12 top young scientists 2Health News:Damon Runyon Cancer Research Foundation awards prestigious fellowships to 12 top young scientists 3Health News:Damon Runyon Cancer Research Foundation awards prestigious fellowships to 12 top young scientists 4Health News:Study Sheds Light on Genetic Risk of MS 2Health News:Malfunctioning gene associated with Lou Gehrig's disease leads to nerve-cell death in mice 2
Stylet tube, endotracheal, sterile, stainless steel, malleable, one size, overall length 13"(33cm)....
SunGlide™ Stylette - Green Adult. Use in 7.0 to 10mm tubes. 25/box....
SunGlide™ Stylette - Blue Neonatal. Use in 2.0 to 3.5mm tubes. 25/box....
Disposable Aluminum Satin Finish E/T Stylette, Adult 16, 25/box....
Medicine Products: